Experienced in Hypersensitivity Vasculitis

Dr. Michael D. Kohen

Allergy and Immunology | Rheumatology
Michael D. Kohen MD PA
709 N Clyde Morris Blvd, 
Daytona Beach, FL 
 (2148.2 mi)
Accepting New Patients
Offers Telehealth
Experienced in Hypersensitivity Vasculitis
Michael D. Kohen MD PA
709 N Clyde Morris Blvd, 
Daytona Beach, FL 
 (2148.2 mi)
OverviewInsuranceLocationsClinical Research

Overview

Michael Kohen is an Allergy and Immunologist and a Rheumatologist in Daytona Beach, Florida. MD. Kohen and is rated as an Experienced provider by MediFind in the treatment of Hypersensitivity Vasculitis. His top areas of expertise are Rheumatoid Arthritis (RA), Psoriasis, Juvenile Temporal Arteritis, and Polymyositis. MD. Kohen is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Florida College Of Medicine
Specialties
Allergy and Immunology
Rheumatology
Licenses
Allergy & Immunology in FL
Hospital Affiliations
Adventhealth Orlando
Halifax Health Medical Center
Adventhealth Daytona Beach
Adventhealth New Smyrna Beach
Florida Hospital Flagler
Languages Spoken
English
Cantonese
Mandarin
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Florida Health
  •  Health First
  •  Blue Cross Blue Shield
  •  Health Options
  •  Oscar
  •  Humana
View 1 More Insurance +

Locations

MICHAEL D. KOHEN MD PA
709 N Clyde Morris Blvd, Daytona Beach, FL 32114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Drug, Other
Study Drug: VIB7734
Study Phase: Phase 2
A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus
A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Drug
Study Drug: TAK-079
Study Phase: Phase 1
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 4 Less Clinical Trials

1 Total Publications

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.
Journal: Arthritis research & therapy
Published: August 17, 2011
Similar Doctors
Experienced in Hypersensitivity Vasculitis
Dr. Miguel A. Gonzalez
Rheumatology
Experienced in Hypersensitivity Vasculitis
Dr. Miguel A. Gonzalez
Rheumatology
920 Rolling Acres Rd, Unit 207, 
Lady Lake, FL 
 (56.2 mi)
352-314-2999
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Miguel Gonzalez is a Rheumatologist in Lady Lake, Florida. Dr. Gonzalez and is rated as an Advanced provider by MediFind in the treatment of Hypersensitivity Vasculitis. His top areas of expertise are Rheumatoid Arthritis (RA), Necrotizing Vasculitis, Psoriatic Arthritis, and Psoriasis. Dr. Gonzalez is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile